Despite the International Ki67 in Breast Cancer Working Group attributing limited clinical utility to Ki67 expression for treatment decision-making17, it guided BCMS use in over two-thirds of hospitals where panellists practiced. The gene discussed is MKI67; the disease is breast carcinoma.